-
On 13 June 2025, the Philippine Department of Finance announced an expanded VAT exemption for medicines treating cancer, diabetes, dialysis, hypertension, high cholesterol, and mental illnesses, following President Marcos Jr.’s universal healthcare directive.
-
Finance Secretary Recto directed the Bureau of Internal Revenue to promptly implement the exemption, emphasizing reduced out-of-pocket expenses and greater healthcare accessibility, especially benefiting underprivileged Filipinos needing costly treatments and long-term medication.
-
The Bureau of Internal Revenue published the updated VAT-exempt medicine list on 4 June 2025, covering specific drugs like Tegafur combinations, Metformin Hydrochloride+Teneligliptin, Atorvastatin+Fenobribrate, Metoprolol tartrate+Ivabradine, and Lamotrigine for mental health.
Source: Orbitax
Latest Posts in "Philippines"
- Philippines Proposes VAT Reduction to 10% to Combat Inflation and Boost Economy
- AstraZeneca Secures ₱37M VAT Refund from BIR for Exempted Medicine Imports
- Philippine Court Grants Partial VAT Refund to AstraZeneca Subsidiary for 2020 Drug Imports
- Philippines Launches VAT Portal for Non-Resident Digital Service Providers to Enhance Compliance
- Philippines Announces VAT Exemption on Medicines to Lower Healthcare Costs and Improve Access
